113 related articles for article (PubMed ID: 9658722)
1. CD27 in B-cell chronic lymphocytic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily.
Molica S; Vitelli G; Levato D; Crispino G; Dell'Olio M; Dattilo A; Matera R; Gandolfo GM; Musto P
Haematologica; 1998 May; 83(5):398-402. PubMed ID: 9658722
[TBL] [Abstract][Full Text] [Related]
2. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells.
Kato K; Chu P; Takahashi S; Hamada H; Kipps TJ
Exp Hematol; 2007 Mar; 35(3):434-42. PubMed ID: 17309824
[TBL] [Abstract][Full Text] [Related]
3. Clinico-biological implications of increased serum levels of interleukin-8 in B-cell chronic lymphocytic leukemia.
Molica S; Vitelli G; Levato D; Levato L; Dattilo A; Gandolfo GM
Haematologica; 1999 Mar; 84(3):208-11. PubMed ID: 10189383
[TBL] [Abstract][Full Text] [Related]
4. Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis.
Molica S; Levato D; Dell'Olio M; Matera R; Minervini M; Dattilo A; Carotenuto M; Musto P
Haematologica; 1996; 81(5):428-33. PubMed ID: 8952156
[TBL] [Abstract][Full Text] [Related]
5. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
6. Increased levels of soluble CD27 in the cerebrospinal fluid are not diagnostic for leptomeningeal involvement by lymphoid malignancies.
van den Bent MJ; Lamers CH; van 't Veer MB; Sillevis Smitt PA; Bolhuis RL; Gratama JW
Ann Hematol; 2002 Apr; 81(4):187-91. PubMed ID: 11976819
[TBL] [Abstract][Full Text] [Related]
7. Intracellular tumor necrosis factor production by T- and B-cells in B-cell chronic lymphocytic leukemia.
Bojarska-Junak A; Rolinski J; Wasik-Szczepaneko E; Kaluzny Z; Dmoszynska A
Haematologica; 2002 May; 87(5):490-9. PubMed ID: 12010662
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma.
Widney D; Gundapp G; Said JW; van der Meijden M; Bonavida B; Demidem A; Trevisan C; Taylor J; Detels R; Martínez-Maza O
Clin Immunol; 1999 Nov; 93(2):114-23. PubMed ID: 10527687
[TBL] [Abstract][Full Text] [Related]
9. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules.
Trentin L; Zambello R; Sancetta R; Facco M; Cerutti A; Perin A; Siviero M; Basso U; Bortolin M; Adami F; Agostini C; Semenzato G
Cancer Res; 1997 Nov; 57(21):4940-7. PubMed ID: 9354461
[TBL] [Abstract][Full Text] [Related]
10. High levels of serum soluble CD27 correlated with renal dysfunction.
Nakatsuji T
Clin Exp Med; 2003 Feb; 2(4):192-6. PubMed ID: 12624711
[TBL] [Abstract][Full Text] [Related]
11. Comparative flow cytometric evaluation of bcl-2 oncoprotein in CD5+ and CD5- B-cell lymphoid chronic leukemias.
Molica S; Mannella A; Crispino G; Dattilo A; Levato D
Haematologica; 1997; 82(5):555-9. PubMed ID: 9407720
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of biological variables in B-cell chronic lymphocytic leukemia. Can we improve upon clinical parameters?
Molica S
Haematologica; 1997; 82(6):705-9. PubMed ID: 9499672
[TBL] [Abstract][Full Text] [Related]
13. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
Kusenda J; Babusíková O
Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic characterization of the leukemic B-cells from Iranian patients with chronic lymphocytic leukemia: association between CD38 expression and disease progression.
Hojjat Farsangi M; Jeddi-Tehrani M; Razavi SM; Sharifian RA; Shamsian Khoramabadi A; Rabbani H; Shokri F
Iran J Immunol; 2008 Mar; 5(1):25-35. PubMed ID: 18319522
[TBL] [Abstract][Full Text] [Related]
15. Clinico-prognostic implications of increased levels of soluble CD54 in the serum of B-cell chronic lymphocytic leukemia patients. Results of a multivariate survival analysis.
Molica S; Levato D; Dell' Olio M; Cascavilla N; Matera R; Minervini M; Dattilo A; Carotenuto M; Musto P
Haematologica; 1997; 82(2):148-51. PubMed ID: 9175316
[TBL] [Abstract][Full Text] [Related]
16. Expression of thrombospondin receptor (CD36) in B-cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination.
Rutella S; Rumi C; Puggioni P; Barberi T; Di Mario A; Larocca LM; Leone G
Haematologica; 1999 May; 84(5):419-24. PubMed ID: 10329920
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia.
Lai R; O'Brien S; Maushouri T; Rogers A; Kantarjian H; Keating M; Albitar M
Cancer; 2002 Sep; 95(5):1071-5. PubMed ID: 12209693
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia.
Ibrahim S; Jilani I; O'Brien S; Rogers A; Manshouri T; Giles F; Faderl S; Thomas D; Kantarjian H; Keating M; Albitar M
Cancer; 2003 Apr; 97(8):1914-9. PubMed ID: 12673718
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocytic leukemia.
Wolowiec D; Ciszak L; Kosmaczewska A; Bocko D; Teodorowska R; Frydecka I; Kuliczkowski K
Haematologica; 2001 Dec; 86(12):1296-304. PubMed ID: 11726322
[TBL] [Abstract][Full Text] [Related]
20. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
Jabłońska E; Kiersnowska-Rogowska B; Rogowski F; Parfieńczyk A; Puzewska W; Bukin M
Rocz Akad Med Bialymst; 2005; 50():204-7. PubMed ID: 16358967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
